A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Subscribe To Our Newsletter & Stay Updated
